AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

MESOBLAST LTD

2.040

+0.0402.00%

Volume:8.96M

Turnover:18.12M

Market Cap:2.60B

PE:-13.95

High:2.080

Open:2.050

Low:1.925

Close:2.000

Loading ...

Overview Company News Filings

The 4 most popular shares on the ASX today: Do you own them?

ASX Growth Companies With High Insider Ownership In October 2024

Simply Wall St.

Why Insignia, Light & Wonder, Mesoblast, and Woodside shares are racing higher today

6 ASX 300 shares that hit new 52-week highs today

2 ASX healthcare shares rocketing over 16% on Big US news

3 High Growth ASX Stocks With Significant Insider Ownership

Simply Wall St.

3 High Growth ASX Stocks With Significant Insider Ownership

Simply Wall St.

Mesoblast to Raise $50 Million via Convertible Notes to Fund Ryoncil Launch; Shares Up 3%

MT Newswires Live

BUZZ-Australia's Mesoblast jumps most in 2 months on capital raise

BRIEF-Mesoblast Updates On Option To Issue Up To $50M Convertible Notes

Cashed up & ready to go: Mesoblast forges funding deal with top shareholder

The Market Herald

Mesoblast Option to Issue up to US$50 Million Convertible Notes for Product Launch

THOMSON REUTERS

Mesoblast Ltd - Mesoblast Option to Issue up to US$50M Convertible Notes

THOMSON REUTERS

Mesoblast - to Issue Convertible Notes in Tranches of US$10 Mln at Any Time Following an FDA Approval of Ryoncil for a 90-Day Period

THOMSON REUTERS

If you'd invested $6,000 in the ASX 300 stock in January, you'd have $22,551 today!

Mesoblast Ltd : Maxim Group Raises to Buy From Hold

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/MSB.AU/news?page=10"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MSB.AU"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MSB.AU\",,,,,undefined,":{"symbol":"MSB.AU","market":"AU","secType":"STK","nameCN":"MESOBLAST LTD","latestPrice":2.04,"timestamp":1741756320000,"preClose":2,"halted":0,"volume":8962083,"delay":0,"changeRate":0.02,"change":0.04,"floatShares":724336294,"shares":1274447688,"eps":-0.14619951,"lyrEps":-0.141252,"pbRate":3.56,"amount":18124163,"amplitude":0.0775,"volumeRatio":0.7644493275081351,"dividePrice":0,"prevYearClose":3.1,"fiveDayClose":2.4,"twentyDayClose":2.97},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MSB.AU\",,,,,undefined,":{"symbol":"MSB.AU","floatShares":724336294,"roa":"-4.85%","roe":"-21.31%","lyrEps":-0.141252,"volumeRatio":0.7644493275081351,"shares":1274447688,"dividePrice":0,"high":2.08,"amplitude":0.0775,"preClose":2,"low":1.925,"week52Low":0.325,"pbRate":"3.56","psRate":"289.37","week52High":3.37,"institutionHeld":0,"latestPrice":2.04,"committee":-0.988427,"eps":-0.14619950687397398,"divideRate":0,"volume":8962083,"delay":0,"ttmEps":-0.14619950687397398,"open":2.05,"prevYearClose":3.1,"prevWeekClose":2.09,"prevMonthClose":2.52,"prevQuarterClose":3.1,"fiveDayClose":2.4,"twentyDayClose":2.97,"sixtyDayClose":1.615},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MSB.AU\",params:#limit:5,,,undefined,":[{"date":"2025-02-26","symbol":"MSB.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1740524400000,"name":null,"time":"","dateTimestamp":1740488400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MSB.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MSB.AU\",pageSize:16,pageCount:10,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2472600117","title":"The 4 most popular shares on the ASX today: Do you own them?","url":"https://stock-news.laohu8.com/highlight/detail?id=2472600117","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2472600117?lang=en_us&edition=fundamental","pubTime":"2024-10-04 12:53","pubTimestamp":1728017609,"startTime":"0","endTime":"0","summary":"The ASX is buzzing on Friday with several popular shares catching plenty of attention as investors trade their interests between each other. Four stocks stand out as being Friday's 'most popular' at the time of writing. Here, we define the popularity contest as those stocks with the highest trading turnover in dollar terms relative to the corresponding gain in share price. ASX stocks in the red aren't included. They aren't the popular kids here today. According to CommSec data, shares inMesoblast Ltd,Light & Wonder Inc,Santos Ltd, andWoodside Energy Group Ltd show up after applying this filter. Are they part of your portfolio?","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/10/04/the-4-most-popular-shares-on-the-asx-today-do-you-own-them/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7501","WDS.AU","BK7508","MSB.AU","STO.AU","BK7078","LNW.AU","BK7507","BK7142","BK7067"],"gpt_icon":0},{"id":"2472160480","title":"ASX Growth Companies With High Insider Ownership In October 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2472160480","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2472160480?lang=en_us&edition=fundamental","pubTime":"2024-10-04 11:34","pubTimestamp":1728012893,"startTime":"0","endTime":"0","summary":"The Australian market has been experiencing a mixed performance, with the ASX200 down 0.75% at 8,140 points amid geopolitical tensions in the Middle East that have caused oil prices to surge. While the Energy sector has benefited from these developments, other sectors like Materials and Financials are facing declines, highlighting the importance of strategic stock selection during such volatile times. In this context, growth companies with high insider ownership can be appealing as they often indicate strong confidence from those closest to the business and may offer resilience in uncertain markets.Top 10 Growth Companies With High Insider Ownership In Australia. Click here to see the full list of 102 stocks from our Fast Growing ASX Companies With High Insider Ownership screener.Overview: Mesoblast Limited is involved in the development of regenerative medicine products across Australia, the United States, Singapore, and Switzerland with a market cap of A$1.54 billion.Operations: The ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/8ou9h1aPnDmM7LIetWUw9Q--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/3eb1acfa01a97be66f224c62f2ff60fd","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/8ou9h1aPnDmM7LIetWUw9Q--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/3eb1acfa01a97be66f224c62f2ff60fd"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/asx-growth-companies-high-insider-033453248.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK7104","MESO","XJO.AU","XKO.AU","BK7507","BK7093","BK7129","BK7504","CUV.AU","BK7508","CYL.AU","HGO.AU","BK7095","MIN.AU","LTR.AU","BK7067","PLT.AU","ACR.AU","BK7016","AVA.AU","AV1.AU","GEN.AU","BK7084","VSL.AU","XAO.AU","BK7501","BK7096","MSB.AU","3DP.AU"],"gpt_icon":1},{"id":"2472605869","title":"Why Insignia, Light & Wonder, Mesoblast, and Woodside shares are racing higher today","url":"https://stock-news.laohu8.com/highlight/detail?id=2472605869","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2472605869?lang=en_us&edition=fundamental","pubTime":"2024-10-04 10:29","pubTimestamp":1728008995,"startTime":"0","endTime":"0","summary":"In afternoon trade, theS&P/ASX 200 Index (ASX: XJO) is out of form and sinking into the red. The benchmark index is currently down 0.8% to 8,142.4 points. Four ASX shares that are not letting that hol","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/10/04/why-insignia-light-wonder-mesoblast-and-woodside-shares-are-racing-higher-today/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK4139","XJO.AU","BK4150","LU2065171311.SGD","LNW.AU","BK7511","ANZ.AU","BK7078","IFL.AU","BK7142","ALL.AU","LNW","LU2065169927.USD","MSB.AU","BK7067","MESO","LU2065170008.USD","BK7501","BK7508","BK7135","WDS.AU","BK7062","LU2065171402.SGD"],"gpt_icon":1},{"id":"2472663315","title":"6 ASX 300 shares that hit new 52-week highs today","url":"https://stock-news.laohu8.com/highlight/detail?id=2472663315","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2472663315?lang=en_us&edition=fundamental","pubTime":"2024-10-03 15:17","pubTimestamp":1727939854,"startTime":"0","endTime":"0","summary":"The S&P/ASX 300 Index (ASX: XKO) finished just inside the green on Thursday, up 0.07% to 8,146 points. In a lacklustre day of trading, these six companies stood out by hitting new price benchmarks tod","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/10/03/6-asx-300-shares-that-hit-new-52-week-highs-today/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["GMG.AU","BK7064","TNE.AU","BK7016","REIT","XKO.AU","BK7155","MSB.AU","REIT.AU","BK7510","BK7103","BK7501","SIG.AU","BXB.AU","BK7099","BK7113","BK7503","BK7067","REG.AU","BK7508"],"gpt_icon":0},{"id":"2472638329","title":"2 ASX healthcare shares rocketing over 16% on Big US news","url":"https://stock-news.laohu8.com/highlight/detail?id=2472638329","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2472638329?lang=en_us&edition=fundamental","pubTime":"2024-10-03 09:07","pubTimestamp":1727917623,"startTime":"0","endTime":"0","summary":"There have been some big moves in the healthcare sector on Thursday.For example, the two ASX healthcare shares listed below are up at least 16% in morning trade thanks to big news in the United States.The Cyclopharm share price is up 18% to $1.80. Investors have been buying the ASX healthcare share this morning after it announced an interim agreement to supply the Veterans Health Administration  with the pharmaceutical and consumable components of Technegas.This could be a very big deal for Cyclopharm given that the VA is the largest integrated US Government health care system in the United States.According to the release, the interim agreement immediately provides the 120 Veterans Affairs hospitals, which have nuclear medicine departments, access to an agreed contract for these products.The ASX healthcare share's CEO and managing director, Doug Ward, commented,Special mention goes to fellow ASX healthcare share Mesoblast Ltd , which is rising over 9% today. However, with no news out o","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/10/03/2-asx-healthcare-shares-rocketing-over-16-on-big-us-news/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["CLIA","LDX.AU","BK7501","BK7067","BK7508","MSB.AU","CYC.AU","BK7007","BK7126"],"gpt_icon":1},{"id":"2472031315","title":"3 High Growth ASX Stocks With Significant Insider Ownership","url":"https://stock-news.laohu8.com/highlight/detail?id=2472031315","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2472031315?lang=en_us&edition=fundamental","pubTime":"2024-10-03 03:05","pubTimestamp":1727895903,"startTime":"0","endTime":"0","summary":"The Australian stock market recently saw the ASX200 dip slightly by 0.15%, influenced by geopolitical tensions in the Middle East, which impacted most sectors but boosted energy stocks. In this fluctuating environment, identifying growth companies with significant insider ownership can be crucial for investors seeking stability and potential upside, as such ownership often signals confidence from those closest to the company's operations.Top 10 Growth Companies With High Insider Ownership In Australia. Click here to see the full list of 101 stocks from our Fast Growing ASX Companies With High Insider Ownership screener.Overview: Mineral Resources Limited, with a market cap of A$10.25 billion, operates as a mining services company in Australia, Asia, and internationally through its subsidiaries.Mineral Resources, backed by billionaire Chris Ellison, is exploring asset sales to strengthen its balance sheet amid high net debt. Recent M&A discussions involve potential buyers for its Perth ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/8ou9h1aPnDmM7LIetWUw9Q--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/3eb1acfa01a97be66f224c62f2ff60fd","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/8ou9h1aPnDmM7LIetWUw9Q--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/3eb1acfa01a97be66f224c62f2ff60fd"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/3-high-growth-asx-stocks-190503371.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MSB.AU","LTR.AU","BK4139","MESO","MIN.AU"],"gpt_icon":0},{"id":"2472502239","title":"3 High Growth ASX Stocks With Significant Insider Ownership","url":"https://stock-news.laohu8.com/highlight/detail?id=2472502239","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2472502239?lang=en_us&edition=fundamental","pubTime":"2024-10-03 03:05","pubTimestamp":1727895902,"startTime":"0","endTime":"0","summary":"The Australian stock market recently saw the ASX200 dip slightly by 0.15%, influenced by geopolitical tensions in the Middle East, which impacted most sectors but boosted energy stocks. In this fluctuating environment, identifying growth companies with significant insider ownership can be crucial for investors seeking stability and potential upside, as such ownership often signals confidence from those closest to the company's operations.","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/2052000-choice2-main-header/1585186553865","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2052000-choice2-main-header/1585186553865"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/materials/asx-min/mineral-resources-shares/news/3-high-growth-asx-stocks-with-significant-insider-ownership-2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7501","BK7508","ACR.AU","XAO.AU","AV1.AU","BK7016","LTR.AU","BK7095","HGO.AU","PLT.AU","BK7067","BK7104","BK7507","BK7093","BK7096","MSB.AU","BK7504","CUV.AU","MIN.AU","BK7084","GEN.AU","AVA.AU","BK7129","3DP.AU","XJO.AU","XKO.AU","CYL.AU"],"gpt_icon":0},{"id":"2471847135","title":"Mesoblast to Raise $50 Million via Convertible Notes to Fund Ryoncil Launch; Shares Up 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2471847135","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2471847135?lang=en_us&edition=fundamental","pubTime":"2024-09-30 13:50","pubTimestamp":1727675405,"startTime":"0","endTime":"0","summary":"Mesoblast  signed a convertible note subscription agreement with its largest shareholder, Gregory George, to raise up to $50 million for the commercialization of Ryoncil, according to a Monday filing with the Australian bourse.The funding option is contingent on the approval of the US Food and Drug Administration of Mesoblast's Ryoncil, a product candidate for use as a treatment for children with steroid-refractory acute graft versus host disease.Mesoblast expects a decision on or before the FDA's Prescription Drug User Fee Act goal date of Jan. 7, 2025, the filing said.The notes will be issued in tranches of $10 million following an FDA approval and bear a coupon of 5% per annum. The conversion price will be $9.06 per American depository receipt, equivalent to AU$1.32 per ASX-listed share, representing a 25% premium to Mesoblast's five-day volume-weighted average share price, the filing stated. The notes will mature four years after the first issuance.Mesoblast's shares were up 3% in ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MESO","MSB.AU","BK4139","BK7067","BK7501","BK7508","AUD","BK4125"],"gpt_icon":0},{"id":"2471984682","title":"BUZZ-Australia's Mesoblast jumps most in 2 months on capital raise","url":"https://stock-news.laohu8.com/highlight/detail?id=2471984682","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2471984682?lang=en_us&edition=fundamental","pubTime":"2024-09-30 12:14","pubTimestamp":1727669675,"startTime":"0","endTime":"0","summary":"** Shares of Mesoblast    rise as much as 4.4% to A$1.1750, their highest levels since July 25   ** The biotechnology firm enters into a convertible note subscription agreement to raise $50 mln with its largest shareholder Gregory George   ** Says issue price of A$1.32 per share is at a ~17% premium, as of co's last trading price on Sept 27   ** MSB stock up 270.9% YTD, including current session's moves  ","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XKO.AU","MSB.AU","XAO.AU","BK7067","BK7508","XJO.AU","BK7501"],"gpt_icon":0},{"id":"2471814235","title":"BRIEF-Mesoblast Updates On Option To Issue Up To $50M Convertible Notes","url":"https://stock-news.laohu8.com/highlight/detail?id=2471814235","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2471814235?lang=en_us&edition=fundamental","pubTime":"2024-09-30 10:47","pubTimestamp":1727664469,"startTime":"0","endTime":"0","summary":"Sept 30 (Reuters) - Mesoblast Ltd   :   * MESOBLAST OPTION TO ISSUE UP TO US$50M CONVERTIBLE NOTES   * TO ISSUE CONVERTIBLE NOTES IN TRANCHES OF US$10 MILLION AT ANY TIME FOLLOWING AN FDA APPROVAL OF RYONCIL FOR A 90-DAY PERIOD Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MESO","BK4139","BK7501","BK7067","BK7508","MSB.AU"],"gpt_icon":0},{"id":"2471811169","title":"Cashed up & ready to go: Mesoblast forges funding deal with top shareholder","url":"https://stock-news.laohu8.com/highlight/detail?id=2471811169","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2471811169?lang=en_us&edition=fundamental","pubTime":"2024-09-30 09:20","pubTimestamp":1727659200,"startTime":"0","endTime":"0","summary":"Inflammatory conditions medicine developer Mesoblast  is trading up more than 3% after striking a funding deal with its largest shareholder Gregory George for AUD$72.7 million in convertible notes.The funds will be available for the company to unleash its marketing strategy, once it has US Food and Drug Administration approval for Mesoblast’s lead cellular drug candidate Ryoncil for the treatment of children with steroid refractory acute graft versus host disease, which can be a complication of stem cell transplants.Mesoblast expects that FDA decision will land by early next year.It will access the funding in US$10 million tranches with the scrip value at AUD$1.32 per share, representing a 25% premium to last week’s 5-day average weighted share price.Gregory George is a US investor with the company G to the Fourth Investments.Mesoblast chief executive and founder Dr Silviu Itescu said the support from Mr George was appreciated.“We appreciate the ongoing support from our major sharehold","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/cashed-up-ready-to-go-mesoblast-forges-funding-deal-with-top-shareholder-2024-09-30/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BK4139","BK7508","MSB.AU","MESO","MMAT","BK4141","BK7501","BK7067"],"gpt_icon":0},{"id":"2471897522","title":"Mesoblast Option to Issue up to US$50 Million Convertible Notes for Product Launch","url":"https://stock-news.laohu8.com/highlight/detail?id=2471897522","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2471897522?lang=en_us&edition=fundamental","pubTime":"2024-09-30 08:55","pubTimestamp":1727657736,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240930:nTUA2NCRYP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","BK7501","MSB.AU"],"gpt_icon":0},{"id":"2471891821","title":"Mesoblast Ltd - Mesoblast Option to Issue up to US$50M Convertible Notes","url":"https://stock-news.laohu8.com/highlight/detail?id=2471891821","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2471891821?lang=en_us&edition=fundamental","pubTime":"2024-09-30 08:00","pubTimestamp":1727654403,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240930:nFWN3L914X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK4139","BK7508","BK7501","MESO","MSB.AU"],"gpt_icon":0},{"id":"2471891348","title":"Mesoblast - to Issue Convertible Notes in Tranches of US$10 Mln at Any Time Following an FDA Approval of Ryoncil for a 90-Day Period","url":"https://stock-news.laohu8.com/highlight/detail?id=2471891348","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2471891348?lang=en_us&edition=fundamental","pubTime":"2024-09-30 08:00","pubTimestamp":1727654403,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240930:nFWN3L914X:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","MESO","BK7508","BK7067","BK4139","MSB.AU"],"gpt_icon":0},{"id":"2470474848","title":"If you'd invested $6,000 in the ASX 300 stock in January, you'd have $22,551 today!","url":"https://stock-news.laohu8.com/highlight/detail?id=2470474848","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2470474848?lang=en_us&edition=fundamental","pubTime":"2024-09-27 10:33","pubTimestamp":1727404386,"startTime":"0","endTime":"0","summary":"Here's what's been sending the stock flying higher. FDA helps send ASX 300 stock soaring Most of the meteoric gains in the Mesoblast share price this year came in March and April. In late March, the ASX 300 stock reported on the progress of its remestemcel-L treatment with receiving United States Food and Drug Administration  approval. Mesoblast's remestemcel-L is intended to treat inflammatory diseases, including steroid-refractory acute graft versus host disease and biologic-resistant inflammatory bowel disease. On 26 March, Mesoblast announced the FDA had determined that the results of the additional clinical data from its phase 3 study sufficed to support the resubmission of Mesoblast's proposed Biologics License Application  for remestemcel-L. Shares in the ASX 300 stock closed up 45.5% on the day of the FDA announcement, with investors clearly excited about the drug's potential in the world's top economy. And as word spread, Mesoblast shares kept on charging higher in March, leap","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/09/27/if-youd-invested-6000-in-the-asx-300-stock-in-january-youd-have-22551-today/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["MSB.AU","BLA.AU","BK7501","XKO.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2469462342","title":"Mesoblast Ltd : Maxim Group Raises to Buy From Hold","url":"https://stock-news.laohu8.com/highlight/detail?id=2469462342","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2469462342?lang=en_us&edition=fundamental","pubTime":"2024-09-24 19:35","pubTimestamp":1727177742,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240924:nFWN3L60AA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK7501","BK7508","MSB.AU","BK7067","MESO"],"gpt_icon":0}],"pageSize":16,"totalPage":11,"pageCount":10,"totalSize":162}]}}